Emergent BioSolutions Inc (EBS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Robert G. Kramer
Employees:
2,420
400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD 20879
240-631-3200

Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.

Data derived from most recent annual or quarterly report
Market Cap 412.152 Million Shares Outstanding50.14 Million Avg 30-day Volume 1.289 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-8.05
Price to Revenue0.5315 Debt to Equity1.1628 EBITDA-180.9 Million
Price to Book Value0.4325 Operating Margin-33.4389 Enterprise Value1.488 Billion
Current Ratio1.005 EPS Growth-3.757 Quick Ratio0.482
1 Yr BETA 1.8345 52-week High/Low 36.14 / 7.74 Profit Margin-41.1957
Operating Cash Flow Growth-164.8726 Altman Z-Score0.4027 Free Cash Flow to Firm -239.34 Million
Earnings Report2023-07-31
View SEC Filings from EBS instead.

View recent insider trading info

Emergent BioSolutions Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EBS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-30 by ZOON KATHRYN C
  • 4: filed on 2023-05-30 by WHITE MARVIN L
  • 4: filed on 2023-05-30 by RICHARD RONALD
  • 4: filed on 2023-05-30 by HARSANYI ZSOLT
  • 4: filed on 2023-05-30 by DAYAL SUJATA TYAGI
  • 4: filed on 2023-04-10 by GLESSNER COLEEN
  • 4: filed on 2023-03-06 by Havey Adam
  • 4: filed on 2023-03-06 by Kramer Robert
  • 4: filed on 2023-03-06 by GLESSNER COLEEN
  • 4: filed on 2023-03-06 by Williams Paul Anthony

    • Events (8k)

  • 8-K: filed on 2023-05-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-15:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-29:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SULLIVAN LOUIS W

    • Director
    		 87,265 2023-05-25 1

    HAUER JEROME M

    • Director
    		 57,508 2023-05-25 1

    KATKIN KEITH

    • Director
    		 42,442 2023-05-25 1

    RICHARD RONALD

    • Director
    		 53,684 2023-05-25 2

    HARSANYI ZSOLT CHAIRMAN

    • Officer
    • Director
    		 71,899 2023-05-25 1

    WHITE MARVIN L

    • Director
    		 50,949 2023-05-25 1

    DAYAL SUJATA TYAGI

    • Director
    		 45,699 2023-05-25 3

    ZOON KATHRYN C

    • Director
    		 53,501 2023-05-25 2

    GLESSNER COLEEN EVP, QUALITY & ETHICS, AND CPL

    • Officer
    		 120,154 2023-04-07 3

    LINDAHL RICHARD S EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 99,145 2023-03-02 4

    KRAMER ROBERT PRESIDENT AND CEO

    • Officer
    • Director
    		 293,751 2023-03-02 4

    HAVEY ADAM EVP, BUSINESS OPERATIONS

    • Officer
    		 100,551 2023-03-02 4

    FOX JENNIFER LYNNE EVP, EXT AFF, GC, CORP SEC

    • Officer
    		 105,359 2023-03-02 5

    WILLIAMS PAUL ANTHONY SVP, PRODUCTS BUSINESS

    • Officer
    		 12,378 2023-03-02 4

    SARAN ATUL EVP, CHIEF STRAT & DEV OFFICER

    • Officer
    		 86,645 2023-02-28 3

    STREI KATHERINE EVP, CHIEF HR OFFICER

    • Officer
    		 62,824 2023-02-28 3

    JOULWAN GEORGE A

    • Director
    		 40,244 2022-05-26 0

    EL-HIBRI FUAD

    • Director
    		 4,636,979 2021-12-03 0

    SMITH KAREN L. EVP, CHIEF MEDICAL OFFICER

    • Officer
    		 11,888 2021-05-07 0

    KIRK SEAN EVP, MANUFACTURING & TECH OPS

    • Officer
    		 17,776 2021-03-31 0

    BAILEY SUE

    • Director
    		 24,427 2021-03-04 0

    EMERGENT BIOSOLUTIONS INC.

    • SEAN KIRK, EVP, MANUFACTURING
    		 13,604 2019-05-23 0

    MULLIGAN SEAMUS

    • Director
    		 594,162 2019-03-19 0

    ABDUN-NABI DANIEL CEO

    • Officer
    • Director
    		 144,553 2019-03-04 0

    NIEDERHUBER JOHN

    • Director
    		 No longer subject to file 2016-05-18 0

    LABINGER BARRY EVP, BIOSCIENCES DIV.

    • Officer
    		 25,182 2015-11-13 0

    CHATFIELD STEVEN EVP, BIOSCIENCES

    • Officer
    		 28,000 2013-03-14 0

    INTERVAC, L.L.C.

    • 10% Owner
    		 4,344,250 2012-09-18 0

    ELSEY R DON CHIEF FINANCIAL OFFICER

    • Officer
    		 26,614 2012-03-13 0

    KEESE KYLE EVP, BIOSCIENCES DIVISION

    • Officer
    		 18,759 2011-03-15 0

    LOCKHART STEPHEN SVP PRODUCT DEVELOPMENT

    • Officer
    		 6,980 2010-11-11 0

    BIOPHARM, L.L.C.

    • 10% Owner
    		 No longer subject to file 2010-05-27 0

    ESPOSITO DENISE CLO

    • Officer
    		 0 2009-03-10 0

    BIOLOGIKA, L.L.C.

    • MEMBER 13(D) GROUP OWNING >10%
    		 1,399,764 2008-06-04 0

    ALLBAUGH JOE M

    • Director
    		 0 2008-05-21 0

    MICHIGAN BIOLOGIC PRODUCTS, INC.

    • MEMBER 13(D) GROUP OWNING >10%
    		 1,328,018 2008-01-14 0

    MALIK SHAHZAD

    • Director
    		 14,400 2007-06-14 0

    GIBELLINI MAURO SVP, CORPORATE DEV.

    • Officer
    		 31,027 2007-06-04 0

    APAX EUROPE IV GP CO LTD

    • MEMBER OF 13(D) GROUP
    		 1,455,361 2007-03-08 0

    ARCURI EDWARD EVP & COO

    • Officer
    		 115,083 2006-11-20 0

    ZINK THOMAS SVP & CMO

    • Officer
    		 115,082 2006-11-20 0

    MYERS ROBERT CALVIN

    • MEMBER 13(D) GROUP OWNING >10%
    		 459,196 2006-11-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DAYAL SUJATA TYAGI - Director

    		2023-05-30 19:03:51 -0400 2023-05-25 A 33,847 a 45,699 direct

    HARSANYI ZSOLT - Director - Officer CHAIRMAN

    		2023-05-30 19:04:40 -0400 2023-05-25 A 33,847 a 71,899 direct

    KATKIN KEITH - Director

    		2023-05-30 19:05:11 -0400 2023-05-25 A 33,847 a 42,442 direct

    RICHARD RONALD - Director

    		2023-05-30 19:06:21 -0400 2023-05-25 A 33,847 a 53,684 direct

    SULLIVAN LOUIS W - Director

    		2023-05-30 19:07:26 -0400 2023-05-25 A 33,847 a 87,265 direct

    HAUER JEROME M - Director

    		2023-05-30 19:08:39 -0400 2023-05-25 A 33,847 a 57,508 direct

    WHITE MARVIN L - Director

    		2023-05-30 19:09:18 -0400 2023-05-25 A 33,847 a 50,949 direct

    ZOON KATHRYN C - Director

    		2023-05-30 19:09:56 -0400 2023-05-25 A 33,847 a 53,501 direct

    GLESSNER COLEEN - Officer EVP, QUALITY & ETHICS, AND CPL

    		2023-04-10 19:41:42 -0400 2023-04-07 F 480 a 120,154 direct -6.2074 -17.184 -33.838 0.0 1 -38.1529 29

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 22:15:04 UTC 4.5657 0.4943 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 21:45:04 UTC 4.5657 0.4943 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 21:15:03 UTC 4.5657 0.4943 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 20:45:04 UTC 4.5657 0.4943 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 20:15:06 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 19:45:04 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 19:15:21 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 18:45:03 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 18:15:04 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 17:45:03 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 17:15:05 UTC 4.5969 0.4631 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 16:45:04 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 16:15:04 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 15:45:03 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 15:15:04 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 14:45:04 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 14:15:03 UTC 4.6049 0.4651 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 13:45:04 UTC 4.6044 0.4656 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 13:15:04 UTC 4.6044 0.4656 1500000
    EMERGENT BIOSOLUTIONS INC EBS 2023-05-31 12:45:04 UTC 4.6044 0.4656 1500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Defensive Long Fund EBS -57.0 shares, $-3298.02 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund EBS -953.0 shares, $-101828.05 2021-01-31 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund EBS -1406.0 shares, $-130631.46 2021-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments